Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The United Laboratories International Holdings ( (HK:3933) ) just unveiled an update.
The United Laboratories International Holdings Limited announced the approval of a clinical trial for its new drug, UBT37034, targeting overweight and obesity. This approval, granted by both the China National Medical Products Administration and the U.S. FDA, marks a significant step in the company’s efforts to enhance its competitiveness in the biopharmaceutical industry, potentially benefiting its shareholders.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited operates in the biopharmaceutical industry, focusing on the development of innovative drugs. It is known for its research and development efforts, particularly in creating products that enhance weight loss and overall health.
Average Trading Volume: 18,907,910
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.24B
For detailed information about 3933 stock, go to TipRanks’ Stock Analysis page.